HELSINKI, May 8, 2026 /PRNewswire/ -- Bioretec Ltd Company release 8 May 2026 at 20:40 p.m. EEST

Bioretec Ltd's resolutions of the constitutive meeting of the Board of Directors

At its constitutive meeting held after the Annual General Meeting, the Board of Directors of Bioretec Ltd elected Kustaa Poutiainen as the Chairperson of the Board and David Gill as the Deputy Chairperson.

The members of the committees were elected as follows:

Audit Committee: Päivi Malinen (Chairperson), Michael Piccirillo and David Gill.

Remuneration Committee: Justin Barad (Chairperson), Antti Vasara and Michael Piccirillo.

The Board of Directors assessed the independence of its members in accordance with the Finnish Corporate Governance Code for listed companies. The Board concluded that the members of the Board are independent of Bioretec and its significant shareholders, except for Kustaa Poutiainen, who is assessed to be independent of the company but not of its significant shareholder, Stephen Industries Inc Oy, due to his role as chairperson of the board of Stephen Industries Inc Oy.

Further enquiries

Sarah van Hellenberg Hubar-Fisher, CEO, +31 6 1544 8736
Tuukka Paavola, CFO, +358 50 386 0013

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.

Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.

Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit www.bioretec.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioretec/r/bioretec-ltd-s-resolutions-of-the-constitutive-meeting-of-the-board-of-directors,c4346701

View original content:https://www.prnewswire.co.uk/news-releases/bioretec-ltds-resolutions-of-the-constitutive-meeting-of-the-board-of-directors-302767220.html

Tags

More Like This

Bioretec Ltd's resolutions of the Annual General Meeting

Resolutions of Bioretec Ltd´s Annual General Meeting and the constitutive meeting of the Board of Directors

Resolutions of Bioretec Ltd´s Annual General Meeting and the constitutive meeting of the Board of Directors

Bioretec Ltd's resolutions of the Extraordinary General Meeting

Bioretec's Shareholders' Nomination Board appointed

Proposals of the Shareholders' Nomination Board of Bioretec Ltd to the Annual General Meeting 2026

Bioretec Ltd's schedule for financial reporting and Annual General Meeting in 2026

Bioretec Ltd: Notification pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act (Kustaa Poutiainen)